Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07D

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/131722NOVEL INDOLE DERIVATIVE, METHOD FOR PREPARING SAME, AND COMPOSITION FOR IMPROVING COGNITIVE FUNCTIONS COMPRISING SAME
WO 23.06.2022
Int.Class C07D 209/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
209Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
02condensed with one carbocyclic ring
04Indoles; Hydrogenated indoles
10with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
Appl.No PCT/KR2021/018891 Applicant K-MEDICHEM Inventor LEE, Koo Yeon
The present invention provides a sulfonylalkylindole derivative, a method for preparing same, and a composition for improving cognitive functions, comprising same as an active ingredient. The sulfonylalkylindole derivative, the method for preparing same, and the composition for improving cognitive functions, comprising same as an active ingredient, as a material that simultaneously inhibits acetylcholinesterase and butyrylcholinesterase, according to the present invention, can be effectively used as a material for improving cognitive functions in the field of medicines and health functional foods.
2.WO/2022/131887ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME
WO 23.06.2022
Int.Class C07D 251/24
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
251Heterocyclic compounds containing 1,3,5-triazine rings
02not condensed with other rings
12having three double bonds between ring members or between ring members and non-ring members
14with hydrogen or carbon atoms directly attached to at least one ring carbon atom
24to three ring carbon atoms
Appl.No PCT/KR2021/095123 Applicant SOLUS ADVANCED MATERIALS CO., LTD. Inventor PARK, Woojae
The present invention relates to a novel compound with excellent carrier transport ability, light-emitting ability, and thermal stability, and an organic electroluminescent device that includes the compound in at least one organic material layer and thus has improved characteristics such as improved luminous efficiency, driving voltage, and lifespan.
3.WO/2022/127327BOSUTINIB 1,3-PROPANEDIETHER DIMER IMPURITY AND PREPARATION METHOD THEREFOR
WO 23.06.2022
Int.Class C07D 215/54
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
215Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
02having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
16with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
54attached in position 3
Appl.No PCT/CN2021/123807 Applicant NANJING HUAWE MEDICINE TECHNOLOGY GROUP CO., LTD. Inventor YAO, Jiming
Disclosed in the present invention are a bosutinib 1,3-propanediether dimer impurity and a synthesis process thereof. The synthesis process is simple, the purity is high, raw materials are simple and easy to obtain, the purity of a prepared finished product can reach 99% or above, and a qualified impurity reference substance can be provided for quality control of bosutinib.
4.WO/2022/127807CRYSTAL FORM OF ARYL PHOSPHORUS OXIDE DERIVATIVE FREE BASE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF
WO 23.06.2022
Int.Class C07D 401/12
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
Appl.No PCT/CN2021/138219 Applicant JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. Inventor SHAN, Wenjun
The present application relates to a crystal form of an aryl phosphorus oxide derivative free base, a preparation method therefor and an application thereof, and in particular to a crystal form of a compound represented by general formula (I), a preparation method therefor, a pharmaceutical composition containing a therapeutically effective amount of the compound or the crystal form thereof, and a use thereof as an EGFR inhibitor in preparing drugs for treating cancer-related diseases.
5.WO/2022/132997BICYCLIC PYRAZOLE BRUTON'S TYROSINE KINASE INHIBITORS
WO 23.06.2022
Int.Class A61K 31/4162
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
4151,2-Diazoles
4162condensed with heterocyclic ring systems
Appl.No PCT/US2021/063660 Applicant ABBVIE INC. Inventor DEGOEY, David A.
The present invention provides for compounds of formula (I); wherein A, R1, R2, R4, W, m, and n have any of the values defined herein, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of CLL and/or SLL.
6.WO/2022/133027SUBSTITUTED CYCLOHEXANECARBOXAMIDES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
WO 23.06.2022
Int.Class C07C 235/40
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
235Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
40having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
Appl.No PCT/US2021/063704 Applicant SANOFI Inventor MUELLER, Paul, Justin
Compounds of formula (1) wherein R1 represents a -C(R2)(R3)-[C(R4)(R5)]m-L-R6 group or -R7; and the preparation and the therapeutic uses of the compounds of formula (1) as agonists of TRPM8 receptors, useful especially in the treatment of oropharyngeal dysphagia.
7.WO/2022/126441OXINDOLE DERIVATIVE AND PHARMACEUTICAL USE THEREOF
WO 23.06.2022
Int.Class C07D 209/34
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
209Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
02condensed with one carbocyclic ring
04Indoles; Hydrogenated indoles
30with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
32Oxygen atoms
34in position 2
Appl.No PCT/CN2020/136898 Applicant CHENGDU UNIVERSITY Inventor ZHAO, Lifeng
Provided are an oxindole derivative and a pharmaceutical use thereof. The structure of the oxindole derivative is shown in formula (A). Experimental results show that the provided compound has significantly improved pharmacokinetic properties compared with BIBF1120, has an excellent inhibition effect on VEGFR, FGFR and PDGFR, can be used as an inhibitor of VEGFR, FGFR and/or PDGFR, as an angiogenesis inhibitor, and as a drug for preventing and/or treating various tumors including pharyngeal squamous cell carcinoma, and has wide application prospects.
8.WO/2022/129951PHARMACEUTICAL COMPOUNDS
WO 23.06.2022
Int.Class C07D 451/02
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
451Heterocyclic compounds containing 8-azabicyclo octane, 9-azabicyclo nonane, or 3-oxa-9-azatricyclo nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
02containing not further condensed 8-azabicyclo octane or 3-oxa-9-azatricyclo nonane ring systems, e.g. tropane; Cyclic acetals thereof
Appl.No PCT/GB2021/053372 Applicant HEPTARES THERAPEUTICS LIMITED Inventor FIELDHOUSE, Charlotte
This invention relates to compounds that are agonists of the muscarinic M1 and M4 receptor and which are useful in the treatment of diseases mediated by the muscarinic M1 and/or M4 receptors. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula (1): and salts thereof.
9.WO/2022/131346COMPOUND AND COMPOSITION
WO 23.06.2022
Int.Class C07D 487/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
487Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
Appl.No PCT/JP2021/046616 Applicant ADEKA CORPORATION Inventor SAITO, Hiromasa
The purpose of the present invention is to provide a composition for forming a cured product having excellent heat resistance and solvent resistance. The present invention provides a compound that is represented by general formula (I) and that has one or more reactive groups in a molecule. In the formula, A represents a C6 hydrocarbon ring; X1 and X2 each represent a reactive group, a C6-30 aryl group in which a group having a reactive group may be substituted, or the like; R1, R2, R3, R4, R6, R7, R8, and R9 each represent a hydrogen atom, a reactive group, a C1-20 hydrocarbon group in which a reactive group may be substituted, or the like; and R5 and R10 each represent a hydrogen atom, a C1-20 hydrocarbon group in which a reactive group may be substituted, or the like.
10.WO/2022/132696UREA OREXIN RECEPTOR AGONISTS
WO 23.06.2022
Int.Class A61K 31/407
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
407condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
Appl.No PCT/US2021/063205 Applicant MERCK SHARP & DOHME CORP. Inventor ARMACOST, Kira, A.
The present invention is directed to urea compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.